Commence safety and efficacy trials in Epidermolysis Bullosa patients
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 12 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- 30 Sep 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“plans to commence safety and efficacy trials in Epidermolysis Bullosa patients this calendar year”
What we found
Evidence strength A What the grades mean
Filings state the Phase 2 trial of INM-755 cream in EB was commenced on September 30, 2021, before the December 31, 2021 deadline.
-
A InMed Pharmaceuticals Inc. 8-K filed 2022-01-05
“which we initiated in September of 2021.” ✓ confirmed on the page
-
A InMed Pharmaceuticals Inc. 10-Q filed 2022-05-13
“On September 30, 2021, we announced that we commenced our Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”)” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Commence
- Deliverable
- Safety and efficacy trials in Epidermolysis Bullosa patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to regulatory approval
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you InMed Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-INM-023741 · Corrections policy